Skip to content

Belite Bio

US · BLTE #1866 by market cap Listed 2022
156.08 +0.47 +0.30%
Live - 5344 symbols - heartbeat 36s ago · 2026-10-08 08:39
Pre-market 156.96 +0.56%
After-hours 156.08 0.00%
Market cap
6.29B
P/B
8.09
EPS
-2.31
Reader sentiment Are you bullish or bearish on BLTE?

Anonymous reader poll. Unscientific, not investment advice.

About Belite Bio

Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Founded
2018
CEO
Dr. Yu-Hsin Lin
Employees
41
Headquarters
San Diego, California, United States of America
Fiscal year end
12-31
Website
belitebio.com

Company profile

Exchange
US
Symbol
BLTE
Market-cap rank
#1866
Listing date
2022-04-29
Market cap
6.29B
Float cap
3.05B
Shares out
40.27M
Float shares
19.55M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:39:33 · For reference only, not investment advice and not tailored to your situation.